Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Immuno-Oncology Market Insights
3.1. Immuno oncology– Industry snapshot
3.2. Immuno oncology -Ecosystem analysis
3.3. Immuno-Oncology Market dynamics
3.3.1. Immuno oncology– Market Forces
3.3.1.1. Immuno-Oncology Market driver analysis
3.3.1.2. Immuno-Oncology Market restraint/challenges analysis
3.3.1.3. Immuno-Oncology Market opportunity analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Immuno-Oncology Market PEST analysis, 2017
3.5.1. Value Chain Analysis
3.5.2. Immuno oncology Industry trends
3.5.3. Prevalence of erectile dysfunction
4. Immuno-Oncology Market Size and Forecast by Treatment Approaches
4.1. Key findings
4.2. Monoclonal Antibodies
4.2.1. Global market estimates and forecasts, 2017 – 2025
4.3. Therapeutic Vaccines
4.3.1. Global market estimates and forecasts, 2017 – 2025
4.4. Checkpoint Inhibitors
4.4.1. Global market estimates and forecasts, 2017 – 2025
4.5. Cytokines
4.5.1. Global market estimates and forecasts, 2017 – 2025
5. Immuno-Oncology Market Size and Forecast by Novel Targets
5.1. Key findings
5.2. IDO1i
5.2.1. Global market estimates and forecasts, 2017 – 2025
5.3. LAG-3 CPI
5.3.1. Global market estimates and forecasts, 2017 – 2025
5.4. oncolytic virus
5.4.1. Global market estimates and forecasts, 2017 – 2025
5.5. STING agonist
5.5.1. Global market estimates and forecasts, 2017 – 2025
5.6. TLR agonist
5.6.1. Global market estimates and forecasts, 2017 – 2025
5.7. HDACi
5.7.1. Global market estimates and forecasts, 2017 – 2025
5.8. TIL
5.8.1. Global market estimates and forecasts, 2017 – 2025
5.9. VEGFi
5.9.1. Global market estimates and forecasts, 2017 – 2025
5.10. MEKi
5.10.1. Global market estimates and forecasts, 2017 – 2025
5.11. TIGIT
5.11.1. Global market estimates and forecasts, 2017 – 2025
5.12. CPI
5.12.1. Global market estimates and forecasts, 2017 – 2025
5.13. GITR agonist
5.13.1. Global market estimates and forecasts, 2017 – 2025
5.14. TGF-b trap
5.14.1. Global market estimates and forecasts, 2017 – 2025
5.15. A2AR antagonist/CD73i
5.15.1. Global market estimates and forecasts, 2017 – 2025
6. Immuno-Oncology Market Size and Forecast by Tumor Types
6.1. Key findings
6.2. Melanoma
6.2.1. Global market estimates and forecasts, 2017 - 2025
6.3. Non-Small Cell Lung Cancer
6.3.1. Global market estimates and forecasts, 2017 – 2025
6.4. Renal Cell Carcinoma
6.4.1. Global market estimates and forecasts, 2017 – 2025
6.5. Head & Neck Cancer
6.5.1. Global market estimates and forecasts, 2017 – 2025
6.6. Bladder Cancer
6.6.1. Global market estimates and forecasts, 2017 – 2025
6.7. Classical Hodgkin’s Lymphoma
6.7.1. Global market estimates and forecasts, 2017 – 2025
6.8. Merkel Cell Carcinoma
6.8.1. Global market estimates and forecasts, 2017 - 2025
7. Immuno-Oncology Market Size and Forecast by Regions
7.1. Key findings
7.2. North America
7.2.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.2.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.2.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.2.4. U.S.
7.2.4.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.2.4.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.2.4.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.2.5. Canada
7.2.5.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.2.5.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.2.5.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.2.6. Mexico
7.2.6.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.2.6.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.2.6.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.3. Europe
7.3.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.3.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.3.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.3.4. Germany
7.3.4.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.3.4.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.3.4.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.3.5. UK
7.3.5.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.3.5.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.3.5.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.4. Asia Pacific
7.4.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.4.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.4.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.4.4. China
7.4.4.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.4.4.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.4.4.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.4.5. India
7.4.5.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.4.5.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.4.5.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.4.6. Japan
7.4.6.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.4.6.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.4.6.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.5. Latin America
7.5.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.5.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.5.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.5.4. Brazil
7.5.4.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.5.4.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.5.4.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
7.6. Middle East & Africa
7.6.1. Immuno-Oncology Market by Treatment Approaches (USD Million), 2017 - 2025
7.6.2. Immuno-Oncology Market by Novel Targets (USD Million), 2017 - 2025
7.6.3. Immuno-Oncology Market by Tumor Types (USD Million), 2017 - 2025
8. Company Profiles
8.1. Bristol Myers Squibb
8.1.1. Overview
8.1.2. Financials
8.1.3. Drug Type Benchmarking
8.1.4. Recent Developments
8.2. Merck & Co.
8.2.1. Overview
8.2.2. Financials
8.2.3. Drug Type Benchmarking
8.2.4. Recent Developments
8.3. AstraZeneca
8.3.1. Overview
8.3.2. Financials
8.3.3. Drug Type Benchmarking
8.3.4. Recent Developments
8.4. Roche Holding AGOverview
8.4.1. Financials
8.4.2. Drug Type Benchmarking
8.4.3. Recent Developments
8.5. Pfizer inc.
8.5.1. Overview
8.5.2. Financials
8.5.3. Drug Type Benchmarking
8.5.4. Recent Developments
8.6. Incyte Corporation
8.6.1. Overview
8.6.2. Financials
8.6.3. Drug Type Benchmarking
8.6.4. Recent Developments